Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Avian flu can be transmitted from birds to humans; transmission among humans, however, is limited. The reason may be an eggshell-like mineral layer that the virus acquires due to the high calcium concentration in the intestines of birds.
InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, announced support from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for verification and validation studies on a new potency test for influenza viruses with pandemic potential.
A boosting skin vaccination with a biodegradable microneedle patch and protein constructed from sequences of influenza virus subtypes could improve the effectiveness of conventional influenza vaccines, according to a study led by Georgia State University.
Scientists at The Scripps Research Institute have shown that for the virus that causes the flu, two wrongs can sometimes make a right.
Researchers have developed a new, rapid biosensor for the early detection of even tiny concentrations of the human influenza A (H1N1) virus.
Much is known about flu viruses, but little is understood about how they reproduce inside human host cells, spreading infection. Now, a research team headed by investigators from the Icahn School of Medicine at Mount Sinai is the first to identify a mechanism by which influenza A, a family of pathogens that includes the most deadly strains of flu worldwide, hijacks cellular machinery to replicate.
An international team based at Geneva University Hospitals and at the University of Geneva, Switzerland, has succeeded in defining a "signature" composed of a small number of inflammatory markers that can be monitored in order to understand how a promising anti-Ebola virus vaccine stimulates the immune system.
Scientists from Tomsk Polytechnic University together with their colleagues from St. Petersburg and London have elaborated a new approach to deliver anti-viral RNAi to target cells against H1N1 influenza virus infection.
Vaccines are successful in preventing pandemic flu and reducing the number of patients hospitalised as a result of the illness, a study led by academics at The University of Nottingham has found.
Fewer than half of American adults get vaccinated despite strong recommendations from the Centers for Disease Control and Prevention and widespread availability of free and low-cost vaccines.
The high-dose flu vaccine appeared to be more effective at preventing post-influenza deaths among older adults than the standard-dose vaccine, at least during a more severe flu season, according to a large new study of Medicare beneficiaries published in The Journal of Infectious Diseases.
The 2016 Zika virus outbreak, along with recent outbreaks of SARS, bird flu, H1N1 and Ebola, underscore the importance of being prepared for and responding quickly to infectious diseases. Zika, in particular, poses unique challenges, since its associated birth defects and lack of preventive treatment currently threaten over 60 countries.
"There has been a little flu, but there will be more...we have not seen the worst of it, flu usually peaks in February," said an article in The Philadelphia Inquirer in January.
What if you could design an adaptable, biomaterials-based model of an organ to track its immune response to any number of maladies, including cancer, transplant rejection and the Zika virus? The lab of Ankur Singh, assistant professor in the Sibley School of Mechanical and Aerospace Engineering, has asked - and begun to answer - that very question.
A new study led by scientists at The Scripps Research Institute (TSRI) is the first to show exactly how the drug Arbidol stops influenza infections. The research reveals that Arbidol stops the virus from entering host cells by binding within a recessed pocket on the virus.
To infect its victims, influenza A heads for the lungs, where it latches onto sialic acid on the surface of cells.
Researchers at Houston Methodist kept mice from getting the flu by removing a gene that regulates their immune system.
This year, everyone will have to roll up their sleeves and receive the flu shot via injection, as the Centers for Disease Control and Prevention no longer recommends the nasal flu mist vaccine due to ineffectiveness.
A computer model developed by scientists at the University of Chicago shows that small increases in transmission rates of the seasonal influenza A virus (H3N2) can lead to rapid evolution of new strains that spread globally through human populations.
A study led by St. Jude Children's Research Hospital found that obese mice are not protected against influenza infections by vaccines that include adjuvants, raising concerns about vaccine effectiveness in obese humans who are known to be at an increased risk for severe flu. The findings appear today in the scientific journal mBio.